辉瑞公布2025年第一季度财报,总营收137亿美元,同比下降8%,主要原因是新冠药物Paxlovid销售额下降。研发费用支出也减少12%。辉瑞重申全年收入预计在610亿至640亿美元之间,并宣布新的成本削减计划,预计到2027年节省77亿美元开支。辉瑞通过自动化和人工智能等数字工具以及简化业务流程来实现成本节约,并计划从研发经费中砍掉5亿美元用于重新投资研发管线。在全球医药市场竞争激烈、成本压力...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.